+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

European Journal of Nuclear Medicine 28(12): 1751-1757

Somatostatin (SMS) scintigraphy is widely used for the detection and staging of neuroendocrine tumours. Because of its superior imaging properties, there is growing interest in the use of positron emission tomography (PET) technology for SMS scintigraphy. This study addressed the production of gallium-68 DOTATOC, its biokinetics and its clinical performance in detecting SMS-positive tumours and metastases. A preparation protocol was developed, yielding 40% overall incorporation of (68)Ga into the peptide (DOTATOC). After column filtration, the radiochemical purity exceeded 98%. Eight patients with histologically verified carcinoid tumours were injected with 80-250 MBq of this tracer. PET acquisition was initiated immediately after administration and carried out until 3 h post injection. Images were quantitated using standardised uptake values and target to non-target ratios. Prior to (68)Ga-DOTATOC PET, all patients underwent indium-111 octreotide planar and single-photon emission tomographic (SPET) imaging. Arterial activity elimination was bi-exponential, with half-lives of 2.0 (+/-0.3) min and 48 (+/-7) min. No radioactive metabolites were detected within 4 h in serum. Maximal tumour activity accumulation was reached 70+/-20 min post injection. Kidney uptake averaged <50% compared with spleen uptake. Of 40 lesions predefined by computed tomography and/or magnetic resonance imaging, (68)Ga-DOTATOC PET identified 100%, whereas (111)In-octreotide planar and SPET imaging identified only 85%. Tumour to non-tumour ratios ranged from >3:1 for liver ((111)In-octreotide: 1.5:1) to 100:1 for CNS ((111)In-octreotide: 10:1). With (68)Ga-DOTATOC >30% additional lesions were detected. It is concluded that PET using (68)Ga-DOTATOC results in high tumour to non-tumour contrast and low kidney accumulation and yields higher detection rates as compared with (111)In-octreotide scintigraphy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 045376728

Download citation: RISBibTeXText

PMID: 11734911

DOI: 10.1007/s002590100639

Related references

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. European Journal of Nuclear Medicine 28(12): 1743-1750, 2001

Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET. Nuklearmedizin. Nuclear Medicine 48(3): N17-N18, 2009

Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. Journal of Nuclear Medicine 56(2): 171-176, 2015

Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American Journal of Nuclear Medicine and Molecular Imaging 5(1): 46-55, 2015

Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. Journal of Nuclear Medicine 52(1): 123-131, 2011

Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. Anticancer Research 33(8): 3015-3019, 2013

Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Molecular Imaging and Biology 16(4): 586-594, 2014

Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clinical Nuclear Medicine 39(8): 713-716, 2014

Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 194: 487-496, 2013

Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT. European Journal of Nuclear Medicine and Molecular Imaging 32(9): 1129, 2005

Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate. Cancer BioTherapy and Radiopharmaceuticals 29(3): 108-115, 2014

Quantitative 68Ga-DOTATOC SMS receptor PET and planar 67Ga-DOTATOC SMS receptor scintigraphy in the pre-therapeutical dosimetry of neuroendocrine tumours. Journal of Nuclear Medicine 42(5 Suppl.): 312P, 2001

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 36(1): 48-52, 2009

Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. European Journal of Nuclear Medicine and Molecular Imaging 31(3): 466, 2004

The biokinetics of 169Yb- and 153Sm-labelled somatostatin analogues in comparison with 111In-octreotide Preliminary results. Journal of Labelled Compounds & Radiopharmaceuticals 35: 320-323, 1994